Market Access Strategy at Asembia AXS26 Summit
Connect with Magnolia Market Access to discuss access strategy shaped by policy, payer dynamics, evidence planning, and analytics.
Policy reform, payer influence, and rising evidence expectations are reshaping how therapies achieve coverage and commercial success. At the Asembia AXS26 Summit in Las Vegas, Magnolia Market Access is meeting with biopharma leaders to discuss how access strategy must evolve to keep pace.
Magnolia Market Access’ Perspective
Biopharma teams are facing rising evidence expectations, expanding policy influence, and increasing coverage variability. These forces are reshaping how access strategy must be designed and executed to support durable launch performance.
At Magnolia Market Access, we integrate reimbursement strategy, value and evidence planning, policy insight, and analytics into cohesive access design grounded in real payer dynamics.
What We are Discussing at Asembia
Access as a design decision rather than a downstream function
Policy-driven pricing and reimbursement strategy
Evidence design aligned to payer decision drivers
Coverage risk modeling and payer segmentation
Mapping the broader access decision ecosystem
Why This Matters
Access strategy is no longer a tactical function. Policy shifts, payer consolidation, and expanded evidence requirements are directly influencing coverage decisions and commercial outcomes. Leaders need a structured approach that anticipates coverage risk and strengthens launch confidence.
Request time with our team to discuss your access strategy priorities, launch planning considerations, or coverage challenges at Asembia.
Our team attending Asembia combines strategic experience across reimbursement, evidence, policy, and analytics. We’re available to discuss launch planning, access challenges, and how to design strategy that supports durable coverage and commercial success.
"*" indicates required fields
Meet the Team at Asembia AXS26
Director, Real World Clinical Insights
